Cachet(SZ:002462)2023-10-30 16:00Financial Performance - The company's revenue for Q3 2023 was ¥6,909,939,005.31, representing a decrease of 8.77% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥81,371,767.96, an increase of 4.81% year-on-year, while the net profit after deducting non-recurring gains and losses was ¥79,773,574.32, up by 5.92%[5]. - Net profit for the period was ¥359,694,433.39, a decrease of 9.4% from ¥399,270,710.90 in the previous year[21]. - Earnings per share (EPS) for the quarter was ¥0.81, down from ¥0.85 in the same quarter last year[22]. - The company reported a total comprehensive income of ¥359,694,433.39, down from ¥399,270,710.90 in the previous year[22]. Cash Flow - The operating cash flow net amount reached ¥851,150,028.56, showing a significant increase of 216.94% compared to the previous year[5]. - Cash flow from operating activities totaled ¥26,220,147,651.19, compared to ¥22,107,312,859.71 in the previous year, indicating a significant increase[23]. - The net cash flow from operating activities for Q3 2023 was ¥851,150,028.56, a significant improvement from a negative cash flow of ¥727,857,246.57 in Q3 2022, indicating a turnaround in operational performance[24]. - The cash inflow from financing activities totaled ¥4,270,367,260.97, compared to ¥3,797,361,570.29 in the same quarter last year, marking an increase of approximately 12.4%[24]. - The net increase in cash and cash equivalents for Q3 2023 was ¥71,631,124.41, contrasting with a decrease of ¥613,532,459.61 in Q3 2022, reflecting improved liquidity[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥16,365,313,319.64, a decrease of 1.16% from the end of the previous year[5]. - Total current assets as of September 30, 2023, amount to CNY 14,818,925,906.84, a decrease from CNY 14,995,581,662.91 at the beginning of the year[16]. - Total liabilities decreased to ¥10,270,458,485.11 from ¥10,635,004,233.56, a reduction of approximately 3.44%[18]. - Total liabilities include accounts payable of CNY 4,815,187,449.25, an increase from CNY 4,275,062,587.11, representing a growth of about 12.7%[17]. - Short-term borrowings decreased to CNY 3,272,877,919.06 from CNY 4,018,296,007.77, a reduction of approximately 18.5%[17]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 27,926[13]. - The largest shareholder, China Everbright Medical Health Industry Co., Ltd., holds 14.36% of shares, totaling 41,876,431 shares[13]. - The company has no preferred shareholders as indicated in the report[15]. Operating Costs and Expenses - Total operating revenue for the third quarter reached ¥21,787,656,785.86, an increase of 7.43% compared to ¥20,280,780,046.14 in the same period last year[20]. - Total operating costs amounted to ¥21,245,266,010.18, up from ¥19,736,956,084.97, reflecting a year-over-year increase of 7.65%[20]. - Sales expenses increased to ¥593,100,470.75 from ¥561,282,583.29, reflecting a rise of 5.67%[21]. - Research and development expenses were reported at ¥2,715,829.05, a decrease from ¥2,715,829.05 in the previous year[21]. Investment and Financing Activities - Total cash outflow from investing activities was ¥21,229,210.86, compared to ¥24,601,962.21 in the same period last year, reflecting a decrease of approximately 13.5%[24]. - The net cash flow from financing activities was negative at ¥761,159,468.18, a decline from a positive cash flow of ¥137,790,671.64 in Q3 2022, highlighting challenges in financing[24]. - The cash outflow for dividends and interest payments was ¥332,677,246.76, up from ¥207,474,803.80 in Q3 2022, indicating increased returns to shareholders[24].